Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic reviewVincenzo Di Lauro, Michelino De Laurentiis, Caterina Fontanella et al.|ESMO Open|2022Cited by 40
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologistsMargaret Ottaviano, Vincenzo Montesarchio, Stefano De Falco et al.|Journal for ImmunoTherapy of Cancer|2020Cited by 19
Systemic treatment of malignant gastrointestinal neuroectodermal tumour after childhood neuroblastomaMargaret Ottaviano, Giovannella Palmieri, Rossella Lauria et al.|Anti-Cancer Drugs|2019Cited by 4
105P CDK4/6 inhibitors in hormone receptor-positive, HER2-negative, locally advanced breast cancer (LABC): Biological and clinical activity, and post-surgical approachesSara Parola, C. De Angelis, Martina Pagliuca et al.|Annals of Oncology|2022Cited by 1